Alpha-7 nicotinic acetylcholine receptor-Filamin A complex (α7nAChR-FLNA complex)

The alpha-7 nicotinic acetylcholine receptor (α7nAChR) – Filamin A (FLNA) complex is a pathological protein assembly identified as a key driver of neurotoxicity in Alzheimer's disease (Wang et al., 2012, Journal of Neuroscience). Under normal physiological conditions, FLNA functions as an actin-binding protein essential for cytoskeletal structure, while α7nAChR facilitates cholinergic signaling and synaptic plasticity (Burns et al., 2021, Science Translational Medicine). However, in the presence of soluble amyloid-beta 42 (Aβ42), FLNA undergoes a conformational change that promotes its high-affinity binding to the α7nAChR (Cassava Sciences, 2023). This interaction recruits the receptor into a signaling complex that activates kinases such as glycogen synthase kinase 3 beta (GSK-3β), leading to hyperphosphorylation of tau protein and neuroinflammation (Wang et al., 2017, Neurobiology of Aging). The drug Simufilam (PTI-125) is designed to target this complex by binding to FLNA and restoring its native, non-pathological conformation, thereby disrupting the toxic linkage with α7nAChR (Burns et al., 2021). This therapeutic approach aims to reduce neurodegeneration and improve cognitive function by blocking the downstream effects of Aβ42 signaling (ClinicalTrials.gov, NCT04388254).

Other names

α7nAChR-FLNAFilamin A-alpha7 nicotinic receptor complexPTI-125 target complexAβ42-α7nAChR-FLNA signaling complex

Simufilam binds to Filamin A (FLNA) with high affinity to restore its native, functional conformation, which prevents the pathological association of FLNA with the alpha-7 nicotinic acetylcholine receptor (α7nAChR) and subsequently blocks the toxic signaling cascade induced by amyloid beta (Aβ42).